Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumours

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 189-196

  Bodey, Bela ^a,e   Bodey Jr , Bela ^a   Gröger, Angela M ^b   Siegel, Stuart E ^c   Kaiser, Hans E ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alkaline phosphatase conjugation; Brain tumors; Cell cycle; Immunocytochemistry; Ki 67 antigen; Mean labeling index (MLI); Monoclonal antibody; Primitive neuroectodermal tumor (PNET); Proliferating cell nuclear antigen (PCNA)

Indexed keywords

CYCLINE; KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTE; BRAIN TUMOR; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL KINETICS; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPENDYMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INFANT; MEDULLOBLASTOMA; MELANOCYTE; MITOSIS; NERVE FIBER GROWTH; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ANIMALS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; KI-67 ANTIGEN; MICE; NEUROECTODERMAL TUMORS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 0031059190     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (101)

1. Silverberg E, Boring CC, Squires TS: Cancer statistics, CA-A Cancer J Clinicians 40: 926, 1990.
2. Cooper GM (ed), Elements of human cancer. Jones and Bartlett Publishers, BostonLondon, 1992, pp.7-14.
3. Katsetos CD, Krishna L, Frankfurter A, Karkavelas G, Wolfe DE, Valsamis MP, Schiffer D, Vlachos IN, Urich H: A cytomorphological scheme of differentiating neuronal phenotypes in cerebellar medulloblastomas based on immunolocalization of class III betatubulin isotype (beta III) and proliferating cell nuclear antigen (PCNA)/cyclin. Clinical Neuropathol 14: 72-81, 1995.
4. O'Brien MC Gupta KK, Lee SY, Bolton WE: Use of a multiparametric panel to target subpopulations in a heterogeneous solid tumor model for improved analytical accuracy. Cytometry 21: 76-83, 1995.
5. Oda Y, Tsuneyoshi M: A comparative study of nuclear photometry and proliferating activity in neuroectodermal tumors of bone and Ewing's sarcoma of bone. General Diagnostic Pathol 141: 121-129, 1995
6. Ellis PA, Makris A, Burton SA, Titley J, Ormerod MG, Salter J, Powles TJ, Smith IE, Dowsett M: Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas, Brit J Cancer 73: MO-643, 1996.
7. Oyama T, Take H, Hikino T, lino Y, Nakajima T: Immunohistochemieal expression of metallothionein in invasive breast cancer in relation to proliferate activity, histology and prognosis. Oncol 53: 112-117, 1996.
8. Enzinger FM, Lattes R, Torloni H: Histological typing of soft tissue tumours. World Health Organization, Geneva, 1971, p. 28.
9. Kury G, Carter HW: Autoradiographic study of human nervous system tumors. Arch Pathol 80: 38-42, 1965.
10. Tym R: Distribution of cell doubling times in in vivo human cerebral tumors, Surg Forum 20: 445-447, 1969.
11. Hoshino T, Barker M, Wilson CB, Boldrey EB, Fewer D: Cell kinetics of human gliomas. J Neurosurg.37: 15-26, 1975.
12. Hoshino T, Wilson CB, Rosenblum ML, Barker M: Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. J Neurosurg 43: 127-135, 1975.
13. Böker DK, Stark EJ, Gullotta F, Nadstawek J, Schultheiss R: Immunohistochemical demonstration of the Ki-67-antigen in paraffin-embedded tumor biopsies. Clin Neuropathol 9: 51-54, 1990.
14. Hoshino T, Nagashima T, Cho KG, Murovic JA, Hodes JE, Wilson CB, Edwards MSB, Pitis LH: S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine. Int J Cancer 38: 369-374, 1986.
15. Howard A, Pelc SR: Nuclear incorporation Of 32p as demonstrated by autoradiographs. Expl Cell Res 2: 178-187, 1951.
16. Darzynkiewicz Z: Molecular interactions and cellular changes during the cell cycle. Pharmacol Ther 21: 143-188, 1983.
17. Quastler H, Sherman FG: Cell population kinetics in the intestinal epithelium of the mouse. Exp Cell Res 17: 420-438, 1959.
18. Mlacher E: Autoradiographie in Histologie und Zytologie. Gustav Fischer Verlag, Stuttgart, 1974.
19. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20, 1983.
20. Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, Stein H: Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984.
21. Gerdes J: An immunohistological method for estimating cell growth fractions in rapid histopathological diagnosis during surgery. Int J Cancer 35: 169-171, 1985.
22. Morimura T, Kitz K, Budka H: In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S phase cells by a new in vitro bromodeoxyuridine-labeling technique, and proliferating pool cells by monoclonal antibody Ki-67. Acta Neuropathol 77: 276-282, 1989.
23. Detta A, Hitchcock E: Rapid estimation of the proliferating index of brain tumours. J Neuro-Oncol 8: 245-253, 1990.
24. Waseem NH, Lane DP: Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 96: 121-129, 1990.
25. Burger PC, Shibata T, Kleihues P: The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Amer J Surg Pathol 10: 611-617, 1986.
26. Murovic JA, Nagashima T, Hoshino T, Edwards MS, Davis RL: Pediatric central nervous system tumors: a cell kinetic study with bromodeoxyuridine. Neurosurg 19: 900-904, 1986.
27. Ostertag CB, Volk B, Shibata T, Burger P, Kleihues P: The monoclonal antibody Ki-67 as a marker for proliferating cells in sterotactic biopsies of brain tumours. Acta Neurochir (Wien) 89: 117-121, 1987.
28. Giangaspero F, Doglioni C, Rivano MT, Pileri S. Gerdes J, Stein H: Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67. Acta Neuropathol (Berlin) 74: 179-182, 1987.
29. Zuber P, Hamou MF, Do Tribolet N: Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurg 22: 364-368, 1988.
30. Nishizaki T, Orita T, Saiki M, Furutani Y, Aoki H: Cell kinetics studies of human brain tumours by in vitro labelling using anti-BUdR monoclonal antibody. J Neurosurg 69: 371-374, 1988.
31. Bruner JM: Neuropathology of malignant gliomas. Semin Oncol 21: 126-138, 1994.
32. Davis RL, Onda K, Shubuya M, Lamborn K, Hoshino T: Proliferation markers in gliomas: a comparison of BUDR, Ki-67, and MIB-1 . J Neuro-Oncol 24: 9-12, 1995.
33. Schiffer D, Cavalla P, Di Sapio A, Giordana MT, Mauro A: Mutations and immunohistochemistry of p53 and proliferation markers in astrocytic tumors of childhood. Childs Nerv Sys 11: 517-522, 1995.
34. Kaluza J, Adamek D, Pyrich M: PCNA and protein p53 in recurrent supratentorial glial brain tumors: studies on correlation between morphology and tumor progression. Polish J Pathol 46: 155-161, 1995.
35. Couldwell WT, Weiss MH, Law RE, Hinton DR: Paradoxical elevation of Ki-67 labeling with protein kinase inhibition in malignant gliomas. J Neurosurg 82: 461-468, 1995.
36. Roggendorf W, Schuster T, Pfeiffer J: Proliferative potential of meningiomas determined with the monoclonal antibody Ki-67. Acta Neuropathol (Berlin) 73: 361-364, 1987.
37. Lelle RT, Heidenreich W, Stauch G, Gerdes J: The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinomas. Cancer 59: 83-88, 1987.
38. Ljung BM, Chew K, Deng G, Matsumura K, Waldman F, Smith H: Fine needle aspiration techniques for the characterization of breast cancers. Cancer 74: 1000-1005, 1994.
39. Weikel W, Brumm C, Wilkens C, Beck T, Knapstein PG: Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prevent 19: 446-450, 1995.
40. Remmele W, Muhlfait V, Keul HG: Estimation of the proliferative activity of human breast cancer tissue by means of the Ki-67 and MIB-1 antibodies-comparative studies on frozen and paraffin sections. Virch Arch 426: 435439, 1995.
41. Gorczyca W, Markiewski M, Kram A, Tuziak T, Domagala W: Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fractions. Virch Arch 426: 229-233, 1995.
42. Nomoto M, Yonezawa S, Tokunaga M, Kim YS, Sato E: Mucin antigens expression and KJ-67 labeling in breast cancer: the peculiarity in scirrhous carcinoma. Pathol Internat 45: 233-239, 1995.
43. Costes V, Marty-Ane C, Picot MC, Serre I, Pujol JL, Mary H, Baldet P: Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and Ki-67 labeling study. Human Pathol 26: 740-745, 1995.
44. Oyama T, Mitsudomi T, Mizoue T, Ohgami A, Osaki T, Nakanishi R, Yasumoto K: Proliferating cell nuclear antigen may be superior to argyrophilic nucleolar organizer regions in predicting shortened survival of patients with non-small cell lung cancer. Surg Oncol 4: 83-89, 1995.
45. Scotlandi K, Serra M, Mammi MC, Maurici D, Benini S, Nini G, Campanacci M, Baldini N: Clinical relevance of Ki-67 expression in bone tumors. Cancer 75: 806-814, 1995.
46. Chano T, Ishizawa M, Matsumoto K, Morimoto S, Hukuda S, Okabe H: The identity of proliferating cells in bone tumors with cartilaginous components: evaluation by double-immunohistochemical staining using proliferating cell nuclear antigen and S-100 protein. Euro J Hisiochem 39: 21-30, 1995.
47. Reddy VB, Gattuso P, Aranha G, Carson MJ: Cell proliferation markers in predicting metastases in malignant melanoma. J Cutaneous Pathol 22: 248-251, 1995.
48. Barksdale SK, Stern JB, Haupt HM, Multhaupt H: Proliferative activity in metastatic malignant melanoma: comparison of pre-treatment and post-treatment metastases. J Cutaneous Pathol 22: 354-358, 1995.
49. Stein H, Bonk A, Tolksdorf G, Lennert K, Rodt H, Gerdes J: Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas. J Histochem Cytochem 28: 746-760, 1980.
50. Pileri S, Gerdes J, Rivano MT, Tazzari PL, Magnani M, Gobbi M, Stein H: Immunohistochemical determination of growth fractions in human permanent cell lines and lymphoid tumors: a critical comparison of the monoclonal antibodies OKT9 and Ki-67. Brit J Haematol 65: 271-276, 1987.
51. Miyachi K, Fritzler MJ, Tan EM: Autoantibody to a nuclear antigen in proliferating cells. J Immunol 121: 2228-2234, 1978.
52. Tan EM: Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 33: 167-240, 1982.
53. Klein G, Steiner M, Wiener F, Klein E: Human leukemia-associated anti-nuclear reactivity. Proc Natl Acad Sci USA 71: 685-689, 1974.
54. Lloyd RV, Wilson BS, Varani J, Gaur PK, Moline S, Makari JG: Immunocytochemical characterization of a monoclonal antibody that recognises mitosing cells. Am J Pathol 121: 275-283, 1985.
55. Robbins BA, de la Vega D, Ogata K, Tan EM, Nakamura RM: Immunohistochemical detection proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 111: 841-845, 1987.
56. Hall PA, Levison DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, Waseem NH, Lane DP: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 162: 285-294, 1990.
57. Suzuki K, Katoh R, Kawaoi A: Immunohistochemical demonstration of proliferating cell nuclear antigen (PCNA) in formalin fixed, paraffin embedded sections from rat and human tissues. Acta Histochem Cytochem 25: 13-21, 1992.
58. Zulch KJ: Histological typing of tumours of the central nervous system. World Health Organization, Geneva (International histological classification of tumours, no. 21).
59. Zulch KL: Brain tumors: their biological pathology, 4th edition, Springer, Berlin, 1988.
60. Stahli C, Staehelin T, Miggiano V, Schmidt J, Haring P: High frequencies of antigenspecific hybridomas: dependence on immunization parameters and prediction by spleen cell analysis. J Immunol Methods 32: 297-304, 1980.
61. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison of ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 29: 577-581, 1981.
62. Janckila AJ, Yam LT, Li C-Y: Immunoalkaline phosphatase cytochemistry. Amer J Clin Pathol 84: 476-480, 1985.
63. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
64. Yam LT, Janckila AJ, Epremian BE, Li C-Y: Diagnostic significance of levamisole-resistant alkaline phosphatase in cytochemistry and immunocytochemistry. Amer J Clin Pathol 97: 31-36, 1989.
65. Strashurger CJ, Amir-Zaltsman Y, Kohen F: The avidin-biotin reaction as un universal amplification system in immunoassays. Prog Clin Biol Res 285: 79-100, 1988.
66. Wilchek M, Bayer EA: Introduction to avidin-biotin technology. Methods Enzymol 184: 5-13, 1990.
67. Duhamel RC, Whitchead JS: Prevention of nonspecific binding of avidin. Methods Enzymol 184: 201-207, 1990.
68. Diamandis EP, Christopoulos TK: The biotin-(strept)avidin system: principles and applications in biotechnology. Clin Chem 37: 625-636, 1991.
69. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave men healing of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
70. Shi S-R, Cote C, Kalra KL, Taylor CR, Tandon AK: A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem 40: 787-792, 1992.
71. Perentes E, Rubinstein LJ: Non-specific binding of mouse myeloma IgM immunoglobulins by human myelin sheaths and astrocytcs. Acta Neuropathol (Berlin) 70: 284-288, 1986.
72. Berry MP, Jenkin RDT, Keen CW, Nair BD, Simpson WJ: Radiation treatment for medulloblastoma. A 21-year review. J Neurosurg 55: 43-51, 1981.
73. Silverman CL, Simpson JR: Cerebellar medulloblastoma: the importance of posterior fossa dose to survival and patterns of failure. Int J Radiat Oncol Biol Phys 8: 1869-1876, 1982.
74. Caputy AJ, McCullogh DC, Manz HJ, Patterson K, Hammock MK: A review of the factors influencing the prognosis of medulloblastoma. The importance of cell differentiation. J Neurosurg 66: 80-87, 1987.
75. Laurent JP, Cheek WR: A staging system for primitive neuroectodermal tumor (medulloblastoma) of the posterior fossa in children. Concepts Pediatr Neurosurg 7: 81-92, 1987.
76. Collins VP, Loeffler RK, Tivey H: Observations on growth rates of human tumors. Amer J Radiol 76: 988-996, 1956.
77. Quest DO, Brisman R, Antunes JL, Housepian EM: Period of risk for recurrence of medulloblastoma. J Neurosurg 48: 159-163, 1978.
78. Quest DO: Medulloblastoma: biological characteristics and therapy. Contemp Neurosurg 2: 1-9, 1980.
79. Chang CH, Housepian EM, Herbert C Jr: An operative staging system and a megavoltage radiotherapeutic technique for cerebellar medulloblastomas. Radiol 93: 1351-1359, 1969.
80. Harisiadis L, Chang CH: Medulloblastoma in children: a correlation between staging and results of treatment. Int J Radiat Oncol Biol Phys 2: 833-841, 1977.
81. Bruce DA, Schut L (eds): Cerebellar medulloblastoma, sarcoma and hemangioblastoma. p. 375, In: American Association of Neurological Surgeons. J Neurosurgery, Grune and Stratton, 1982.
82. Rorke LB: The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 42: 1-15, 1983.
83. Louis DM, Edgerton S, Thor AD, Hedley-Whyte ET: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol 81: 675-679, 1991.
84. Hoshino T, Nagashima T, Murovic JA, Wilson CB, Edwards MSB, Gutin PH. Davis RL, DeArmond SJ: In situ cell kinetics studies on human neuroectodermal tumours with bromodeoxyuridine labeling. J Neurosurg 64: 453-459, 1986.
85. Nagashima T, DeArmond SJ, Murovik JA, Hoshino T: Immunocytochemical demonstration of S-phase cells by antibromo-deoxyuridine monoclonal antibody in human brain tumour tissues. Acta Neuropathol 67: 155-159, 1985.
86. Sacchi S, Donelli A, Cocconcelli P, Emilia G, Messerotti A, Piccinini L, Selleri L. Torelli G, Rinaldi G, Torelli U: Monoclonal antibody to 5-bromodeoxyuridine: a sensitive and rapid method tor estimating the amount of S-phase cells. In: Biotechnology in Diagnostics (eds Koprowsky H, Ferrone S, Albertini A.) pp. 65-70. Elsevier Science Publishers, Amsterdam, 1985.
87. Schlote W, Lang C, Mobius HJ: Growth fraction and growth pattern of neuroectodermal tumors as determined with the monoclonal antibody Ki-67. (Abstract) Clin Neuroputhol 7: 207, 1988
88. Deckert M, Reifenberger G. Wechsler W: Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol 115: 179-188, 1989.
89. Hall PA, Levison DA: Review: assessment of cell proliferation in histological material. J Clin Pathol 43: 184-192, 1990.
90. Hoshino T, Kobayashi S, Townsend JJ, Wilson CB: A cell kinetic study on medulloblastomas. Cancer 55: 1711-1713, 1985.
91. Raza A, Preisler HD. Mayers GL, Bankert R: Rapid enumeration of S-phase cells by means of monoclonal antibodies, [letter] N Engl J Med 310: 991, 1984.
92. Kyung CG, Hoshino T, Nagashima T, Murovic JA, Wilson CB: Prediction of tumour doubling time in recurrent meningiomas. J Neurosurg 65: 790-794, 1986.
93. Goz B: The effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells. Pharmacol Rev 29: 249-272, 1977.
94. Szybalski W: X-ray sensitization by halopyrimidine. Cancer Chemother Rep 58: 539-557, 1974.
95. Gratzner HG: Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 218: 474-475, 1991.
96. Assietti R, Butti G, Magrassi L, Dunova M, Riccardi A, Gaetani P: Cell-kinetic characteristics of human brain tumors. Oncol 47: 344-351, 1990.
97. Lazarous DF, Shou M, Unger EF: Combined bromodeoxyuridine immunohistochemistry and Masson trichrome staining: facilitated detection of cell proliferation in viable vs. infarcted myocardium. Biotech Histochem 67: 253-255, 1992.
98. Yu CC, Dublin EA, Camplejohn RS, Levison DA: Optimization of immunohistochemical staining of proliferating cells in parafin sections of breast carcinoma using antibodies to proliferating cell nuclear antigen and the Ki-67 antigen. Analyt Cell Pathol 9: 45-52, 1995.
99. Keshgegian AA, Cnaan A: Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Amer J Clin Pathol 104: 42-49, 1995.
100. Nurse P: Universal control mechanism regulating onset of M-phase. Nature (London) 344: 503-508, 1990.
101. 1 phase of the human cell cycle. Science 257: 1689-1694, 1992.